Evaluation of Pi3k Levels and Mirna124-5p Expression Levels in Serum Samples From Patients With Lung Cancer
| dc.authorscopusid | 57565083500 | |
| dc.authorscopusid | 57194587414 | |
| dc.contributor.author | Akdeniz, F.T. | |
| dc.contributor.author | Avsar, O. | |
| dc.date.accessioned | 2025-04-16T00:05:53Z | |
| dc.date.available | 2025-04-16T00:05:53Z | |
| dc.date.issued | 2025 | |
| dc.department | Okan University | en_US |
| dc.department-temp | Akdeniz F.T., Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, Istanbul Okan University, Istanbul, Turkey; Avsar O., Department of Molecular Biology & Genetics, Faculty of Arts & Science, Hitit University, Corum, Turkey | en_US |
| dc.description.abstract | Background/Aim: Lung cancers are malignant neoplasms located in the lung tissues. miRNAs are short non-coding RNAs. It is known that miRNA-124 prevents metastasis in lung cancers. The phosphatidylinositol 3-kinases (PI3K) signaling pathway, a basic signaling pathway interconnected with other pathways, is activated during cancer development. This study aimed to compare miRNA-124-5p and PI3K serum levels in patient and control groups. Materials and Methods: miRNA isolated from patient and control serum samples were converted into cDNA. miRNA- 124-5p expression was determined using Real-Time PCR and a SYBR GREEN kit. PI3K serum level was determined using the Enzyme-Linked Immunosorbent Assay. Results: While miRNA-124-5p serum level was statistically significantly lower in the patient group (p>0.02), serum PI3K level was higher in the patient group than in the control group but the difference was not statistically significant (p>0.11). Conclusion: Lower serum levels of miRNA-124-5p and high PI3K levels observed in the patient group, compared to the control group, may be associated with a poor disease prognosis. © 2025 The Author(s). Anticancer Research is published by the International Institute of Anticancer Research. | en_US |
| dc.identifier.doi | 10.21873/cdp.10433 | |
| dc.identifier.endpage | 229 | en_US |
| dc.identifier.issn | 2732-7787 | |
| dc.identifier.issue | 2 | en_US |
| dc.identifier.scopus | 2-s2.0-86000055584 | |
| dc.identifier.scopusquality | N/A | |
| dc.identifier.startpage | 223 | en_US |
| dc.identifier.uri | https://doi.org/10.21873/cdp.10433 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14517/7828 | |
| dc.identifier.volume | 5 | en_US |
| dc.identifier.wosquality | N/A | |
| dc.language.iso | en | en_US |
| dc.publisher | International Institute of Anticancer Research | en_US |
| dc.relation.ispartof | Cancer Diagnosis and Prognosis | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Lung Cancer | en_US |
| dc.subject | Mirna124 | en_US |
| dc.subject | Pi3K | en_US |
| dc.subject | Real Time Pcr | en_US |
| dc.title | Evaluation of Pi3k Levels and Mirna124-5p Expression Levels in Serum Samples From Patients With Lung Cancer | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication |